Showing results (251-260 of 319) with videos related to

Sort By:
Pageof 32
Open Forum Infectious Diseases|May 14, 2026
Plasma Extracellular Vesicle Surface Marker Profiling Reveals Immune Cell-Associated Mitochondrial Membrane Potential Alterations in Long COVID and Myalgic Encephalomyelitis/Chronic Fatigue SyndromeGentaro Ikeda, Mariko Koike-Ieki, Hiroyuki Inoue, et al.
Annals of Internal Medicine|August 15, 1994
Human immunodeficiency virus infection among health care workers who donate bloodM E Chamberland, L R Petersen, V P Munn, et al.
The Journal of Infectious Diseases|March 24, 2009
Ultra-deep pyrosequencing of hepatitis B virus quasispecies from nucleoside and nucleotide reverse-transcriptase inhibitor (NRTI)-treated patients and NRTI-naive patientsSeverine Margeridon-Thermet, Nancy S Shulman, Aijaz Ahmed, et al.
AIDS Research and Therapy|May 5, 2012
Standardized representation, visualization and searchable repository of antiretroviral treatment-change episodesSoo-Yon Rhee, Jose Luis Blanco, Tommy F Liu, et al.
Antimicrobial Agents and Chemotherapy|February 15, 2012
Standardized comparison of the relative impacts of HIV-1 reverse transcriptase (RT) mutations on nucleoside RT inhibitor susceptibilityGeorge L Melikian, Soo-Yon Rhee, Jonathan Taylor, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|June 23, 2006
Oxidant stress and peripheral neuropathy during antiretroviral therapy: an AIDS clinical trials group studyTodd Hulgan, Michael Hughes, Xin Sun, et al.
AIDS (London, England)|March 7, 2025
Noncanonical HIV drug resistance mutations: need to close existing gapsSeth Inzaule, Michael R Jordan, Joseph Fokam, et al.
Journal of Acquired Immune Deficiency Syndromes (1999)|September 8, 2009
Minority variants associated with transmitted and acquired HIV-1 nonnucleoside reverse transcriptase inhibitor resistance: implications for the use of second-generation nonnucleoside reverse transcriptase inhibitorsVici Varghese, Rajin Shahriar, Soo-Yon Rhee, et al.
The Journal of Infectious Diseases|January 23, 2020
Expanded Spectrum of Antiretroviral-Selected Mutations in Human Immunodeficiency Virus Type 2Philip L Tzou, Diane Descamps, Soo-Yon Rhee, et al.
The Lancet. HIV|June 21, 2025
Lenacapavir-associated drug resistance: implications for scaling up long-acting HIV pre-exposure prophylaxisGert van Zyl, Mateo Prochazka, Heather-Marie Ann Schmidt, et al.
Pageof 32